Search Results
Jun 18, 2025, 11:00 ET Oligonucleotide Synthesis Market is expected to generate a revenue of USD 5.75 Billion by 2031, Globally, at 10.49% CAGR: Verified Market Research®
Applications in Genomics and Molecular Diagnostics: Oligonucleotides are foundational to genomic technologies, including next-generation sequencing (NGS), CRISPR, and qPCR, which are witnessing strong adoption across research labs, clinical diagnostics, and biotech firms. The COVID-19 pandemic further
More news about: Verified Market Research
Jun 17, 2025, 15:42 ET Infectious Disease Testing Surges to $29B: Kalorama Report Highlights Molecular Breakthroughs and Point-of-Care Growth in IVD Market
and POC innovations." The report highlights the growing impact of next-generation technologies, including alternative PCR methods, microarrays, NGS, and mass spectrometry. Instrument-automated analysis and miniaturized platforms are enabling broader deployment across physician offices, mobile health
More news about: Kalorama Information
Jun 17, 2025, 08:30 ET ePlus Recognized as Lenovo North American Infrastructure Partner of the Year
HERNDON, Va., June 17, 2025 /PRNewswire/ -- ePlus inc. (NASDAQ NGS: PLUS –
More news about: EPLUS INC.
Jun 17, 2025, 06:53 ET European Direct-to-Consumer Genetic Testing Market to Reach USD 3.78 Billion by 2035, Says Meticulous Research®
on personalized nutrition, wellness optimization trends, and growing understanding of gene-diet interactions. Next-Generation Sequencing (NGS) Experiencing Highest Growth by Technology The DNA Microarrays segment is expected to dominate the overall European DTC genetic testing market
More news about: Meticulous Market Research Pvt. Ltd.
Jun 13, 2025, 22:12 ET Gene Solutions 與優聖康達成戰略合作 攜手共建華南區域先進NGS實驗室
聚焦於滿足華南區域醫療體系的差異化診療需求。 優聖康在聚合酶鏈式反應（PCR）類體外診斷（IVD）產品的研發與GMP認證生產方面具備深厚積累。Gene Solutions 則憑借其在 NGS 腫瘤檢測領域的領先優勢，推出了亞洲首個經臨床驗證的多癌種早篩產品 SPOT-MAS，已在9,024名受試者中完成前瞻性研究驗證。此外，公司近期還發佈了一項
More news about: Gene Solutions Genomics Pte Ltd
Jun 12, 2025, 08:17 ET Gene Solutions 攜手鼎晶生物，共同推動中國區精準腫瘤診療進程
本次合作將重點聚焦於臨床驗證、轉化研究和聯合商業化，雙方共同致力於提升區域內癌症患者的治療效果與健康管理水平。 關於鼎晶生物 鼎晶生物是中國領先的精準腫瘤學整體解決方案提供商，總部位於浙江紹興，上海為研發中心，安徽為生產基地，業務覆蓋全國30個省市自治區，合作醫院超過1300家，服務患者超過10萬人次。鼎晶生物整合了qPCR、NGS、dPCR、流式細胞術等技術平台，廣泛應用於癌症早篩、伴隨診斷、遺傳檢測及疾病監測等多個領域。 公司旗下擁有13家控股子公司、3家醫學檢驗所及43家院內精準醫學實驗室，多年連續滿分通過CAP（美國病理學家協會）室間質評和國內臨床基因擴增實驗室認證（PCR實驗室認證）等，形成
More news about: Gene Solutions Genomics Pte Ltd
Jun 09, 2025, 14:15 ET Nontuberculous Mycobacterial (NTM) Diagnostic Market to Reach USD 3,261.1 million By 2032, Growing At An 6.64% CAGR - Credence Research
determinant is the rapid advancement in diagnostic technologies. Innovations in molecular diagnostics, PCR-based assays, and next-generation sequencing (NGS) are enabling faster, more precise identification of various NTM species, overcoming the limitations of traditional culture methods. Furthermore, increased
More news about: Credence Research Inc.
Jun 09, 2025, 10:05 ET Florida Cancer Specialists & Research Institute Launches Liquid Biopsy
Other recent additions to the NGS testing menu at FCS include HRD, or homologous recombination deficiency, which analyzes the DNA of a tumor and determines potential treatment response to PARP inhibitors, a class of drugs that target cancer cells; a small heme NGS panel that detects mutations associated
More news about: Florida Cancer Specialists & Research Institute
Jun 09, 2025, 09:00 ET Sequentify and Bio Molecular Systems Partner to Release InfiniSeq™ Myra Protocol for Automated NGS Library Preparation
used by leading institutions to decentralize genomic testing. "By combining our InfiniSeq protocol with the Myra system, labs can now automate NGS prep in a matter of minutes with minimal training, fewer errors, and significantly higher throughput," said Tamir Biezuner, CSO and Co-founder of Sequentify.
More news about: Sequentify
Jun 06, 2025, 09:13 ET ePlus Receives Nutanix Portfolio Partner of the Year Award
HERNDON, Va., June 6, 2025 /PRNewswire/ -- ePlus inc. (NASDAQ NGS: PLUS –
More news about: EPLUS INC.
Jun 04, 2025, 09:30 ET DPX Technologies Announces New Automated Workflows and Expanded Liquid Handler Compatibility for Genomic Testing
selection and PCR cleanup offer high-yield solutions that serve as efficient alternatives to laborious magnetic bead methods for next generation sequencing (NGS) library preparation and other downstream DNA enzymatic reaction clean ups.COLUMBIA,
More news about: DPX Technologies
May 30, 2025, 10:30 ET Biomarkers Market worth US$104.15 billion in 2030 with 10.8% CAGR | MarketsandMarkets™
decision-making during preclinical and early clinical phases. By PCR technology, the biomarkers market is segmented by technology into immunoassays, NGS, PCR, mass spectrometry, chromatography, and other technologies. PCR technology, which is used for detecting, quantifying, and validating nucleic acid-based
More news about: MarketsandMarkets
May 30, 2025, 08:50 ET Velsera Powers the Knowledgebase Behind Illumina's TSO Comprehensive Test, Now Approved in Japan
approval from Japan's Ministry of Health, Labour and Welfare (MHLW). TSO Comp is a next-generation sequencing (NGS)-based assay that enables comprehensive genomic profiling (CGP) of solid tumors. It detects a wide range of genomic alterations including single nucleotide
More news about: Velsera
May 30, 2025, 07:00 ET Labcorp Expands Oncology Portfolio to Improve Patient Care and Advance Cancer Research
new NGS panels for myeloid, lymphoid and pan-heme indications: These new panels offer broader genomic coverage and more clinically actionable insights
More news about: Labcorp
May 29, 2025, 10:30 ET Electronic Lab Notebook Market worth US$1.03 billion by 2030 with 7.3% CAGR | MarketsandMarkets™
biotechnology companies, contract service organizations, biobanks & biorepositories, clinical research laboratories, academic research institutes, NGS laboratories, and toxicology laboratories. In 2024, the pharmaceutical & biotechnology companies segment accounted for the largest share of the electronic
More news about: MarketsandMarkets
May 28, 2025, 10:00 ET Geneseeq's Breakthrough Cancer Detection Blood Test Published in Nature Medicine
About Geneseeq Geneseeq Technology Inc. is a research-driven global leader in precision oncology, pioneering next-generation sequencing (NGS) technologies to transform cancer detection, diagnosis, and treatment. Its portfolio includes comprehensive genomic profiling for all tumor types, cancer-specific
More news about: Geneseeq Technology Inc.
May 28, 2025, 09:00 ET 1Cell.Ai Completes CLIA Validation Study of OncoIncytes 1080-Gene NGS Panel
demonstrated high concordance with FDA approved orthogonal NGS platforms and consistent performance across FFPE, blood, and bone marrow samples spanning over 15 tumor types. "Our goal was to rigorously validate the OncoIncytes 1080-gene NGS panel across a broad spectrum of cancers and sample types,"
More news about: 1Cell.Ai
May 27, 2025, 16:30 ET ePlus Secures a Spot on CRN Solution Provider 500 List for 14th Consecutive Year
HERNDON, Va., May 27, 2025 /PRNewswire/ -- ePlus inc. (NASDAQ NGS: PLUS –
More news about: EPLUS INC.
May 27, 2025, 10:15 ET Pillar Biosciences Raises $34.5M in Funding
Illumina to provide an expanded menu of research and clinical NGS solutions, accelerating access to precision oncology," " said Ashley Van Zeeland, vice president of Corporate Development Illumina. "Pillar's rapid NGS targeted sequencing panels alongside Illumina's state-of-the-art
More news about: Pillar Biosciences, Inc.
May 26, 2025, 15:11 ET MGI Tech presenta soluzioni multi-omiche complete all'ESHG 2025 di Milano
direttrice del Laboratorio internazionale presso Genekor Medical S.A., in Grecia, ha sottolineato il ruolo trasformativo dei pannelli multigenici basati su NGS nell'oncologia di precisione, che consentono l'identificazione di biomarcatori predittivi e prognostici per promuovere strategie terapeutiche estremamente
More news about: MGI TECH
May 26, 2025, 06:30 ET MGI Tech Showcases Comprehensive Multi-Omics Solutions at ESHG 2025 Milan
Papadopoulou, International Laboratory Director at Genekor Medical S.A. in Greece, highlighted the transformative role of NGS-based multigene panels in precision oncology, enabling the identification of predictive and prognostic biomarkers to drive highly personalized treatment
More news about: MGI TECH
May 23, 2025, 10:53 ET MGI Tech stellt auf der SLAS Europe 2025 in Deutschland das Automatisierungsportfolio der nächsten Generation vor
basierende KI und bietet hochpräzise Leistung bei kritischen Anwendungen wie Nukleinsäureextraktion, Plasmidkonstruktion, Probenvorbereitung und NGS-Bibliotheksvorbereitung. Sie wurde für die globale Zugänglichkeit entwickelt und beseitigt Kosten- und Komplexitätsbarrieren durch ein skalierbares, modulares Design
More news about: MGI TECH
May 22, 2025, 10:30 ET Human Leukocyte Antigen (HLA) Typing for Transplant Market worth US$1.4 billion by 2030 with 6.0% CAGR | MarketsandMarkets™
encompassing PCR-based assays, next-generation sequencing (NGS) platforms, and associated reagents. This robust product portfolio positions QIAGEN to effectively meet the varied demands of transplant centers and clinical laboratories. QIAGEN's NGS-based offerings, such as the QIAseq HLA Typing Panel, invest
More news about: MarketsandMarkets
May 22, 2025, 08:00 ET Golden Helix Launches Enterprise Genomic Analysis with VarSeq 3 and VSWarehouse 3
and multi-site collaboration via fine-grained access control and secure data sharing. Native integrations with cloud object storage and third-party NGS repositories streamline cloud-to-cloud data transfer and federated analysis across institutions and geographies.Per-Sample Licensing OptionsFor
More news about: Golden Helix Inc
May 21, 2025, 22:38 ET MGI Tech Unveils Next-Generation Automation Portfolio at SLAS Europe 2025 in Germany
PrepALL delivers high-precision performance in critical applications such as nucleic acid extraction, plasmid construction, sample preparation, and NGS library prep. Designed for global accessibility, it addresses cost and complexity barriers with a scalable, modular design and open APIs. Ideal for both
More news about: MGI TECH